Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Luigi Naldi

Showing results (191-200 of 289) with videos related to

Pageof 29
Sort By:
Contact Dermatitis|April 11, 2018
Prevalence of contact allergy to metals in the European general population with a focus on nickel and piercings: The EDEN Fragrance StudyMarie L A Schuttelaar, Robert F Ofenloch, Magnus Bruze, et al.
Dermatology (Basel, Switzerland)|September 24, 2008
Impact of body mass index and obesity on clinical response to systemic treatment for psoriasis. Evidence from the Psocare projectLuigi Naldi, Antonio Addis, Sergio Chimenti, et al.
The Cochrane Database of Systematic Reviews|July 12, 2023
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysisEmilie Sbidian, Anna Chaimani, Robin Guelimi, et al.
The Cochrane Database of Systematic Reviews|May 23, 2022
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysisEmilie Sbidian, Anna Chaimani, Ignacio Garcia-Doval, et al.
JAAD International|August 19, 2021
Biosimilars for the treatment of patients with psoriasis: A consensus statement from the Biosimilar Working Group of the International Psoriasis CouncilArnon D Cohen, Ronald Vender, Luigi Naldi, et al.
Journal of the American Academy of Dermatology|January 14, 2015
WITHDRAWN: Experience with ustekinumab in patients with psoriasis enrolled in a large, multicenter, prospective, disease-based registry (Psoriasis Longitudinal Assessment and Registry [PSOLAR])Kim Papp, Alice B Gottlieb, Luigi Naldi, et al.
The Journal of Investigative Dermatology|September 7, 2007
Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-studyMaja Mockenhaupt, Cecile Viboud, Ariane Dunant, et al.
The Journal of Allergy and Clinical Immunology|November 8, 2020
Incidence rates of hospitalization and death from COVID-19 in patients with psoriasis receiving biological treatment: A Northern Italy experiencePaolo Gisondi, Stefano Piaserico, Luigi Naldi, et al.
Journal of Drugs in Dermatology : JDD|July 8, 2015
Safety Surveillance for Ustekinumab and Other Psoriasis Treatments From the Psoriasis Longitudinal Assessment and Registry (PSOLAR)Kim Papp, Alice B Gottlieb, Luigi Naldi, et al.
Recenti Progressi in Medicina|October 2, 2025
Tiziana Pinciroli, Luigi De Angelis, Francesco Andrea Causio, et al.
Pageof 29

Showing results (191-200 of 289) with videos related to

Sort By:
Pageof 29
Contact Dermatitis|April 11, 2018
Prevalence of contact allergy to metals in the European general population with a focus on nickel and piercings: The EDEN Fragrance StudyMarie L A Schuttelaar, Robert F Ofenloch, Magnus Bruze, et al.
Dermatology (Basel, Switzerland)|September 24, 2008
Impact of body mass index and obesity on clinical response to systemic treatment for psoriasis. Evidence from the Psocare projectLuigi Naldi, Antonio Addis, Sergio Chimenti, et al.
The Cochrane Database of Systematic Reviews|July 12, 2023
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysisEmilie Sbidian, Anna Chaimani, Robin Guelimi, et al.
The Cochrane Database of Systematic Reviews|May 23, 2022
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysisEmilie Sbidian, Anna Chaimani, Ignacio Garcia-Doval, et al.
JAAD International|August 19, 2021
Biosimilars for the treatment of patients with psoriasis: A consensus statement from the Biosimilar Working Group of the International Psoriasis CouncilArnon D Cohen, Ronald Vender, Luigi Naldi, et al.
Journal of the American Academy of Dermatology|January 14, 2015
WITHDRAWN: Experience with ustekinumab in patients with psoriasis enrolled in a large, multicenter, prospective, disease-based registry (Psoriasis Longitudinal Assessment and Registry [PSOLAR])Kim Papp, Alice B Gottlieb, Luigi Naldi, et al.
The Journal of Investigative Dermatology|September 7, 2007
Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-studyMaja Mockenhaupt, Cecile Viboud, Ariane Dunant, et al.
The Journal of Allergy and Clinical Immunology|November 8, 2020
Incidence rates of hospitalization and death from COVID-19 in patients with psoriasis receiving biological treatment: A Northern Italy experiencePaolo Gisondi, Stefano Piaserico, Luigi Naldi, et al.
Journal of Drugs in Dermatology : JDD|July 8, 2015
Safety Surveillance for Ustekinumab and Other Psoriasis Treatments From the Psoriasis Longitudinal Assessment and Registry (PSOLAR)Kim Papp, Alice B Gottlieb, Luigi Naldi, et al.
Recenti Progressi in Medicina|October 2, 2025
Tiziana Pinciroli, Luigi De Angelis, Francesco Andrea Causio, et al.
Pageof 29